- Home
- KBR vs WGS Comparison
KBR vs WGS Comparison
Compare KBR & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KBR | WGS |
|---|---|---|
| Founded | 1901 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.6B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | KBR | WGS |
|---|---|---|
| Price | $42.82 | $95.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $53.14 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 1.3M | 722.8K |
| Earning Date | 02-23-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 21.27 | N/A |
| EPS | ★ 2.89 | 0.07 |
| Revenue | ★ $8,041,000,000.00 | $402,190,000.00 |
| Revenue This Year | $2.42 | $41.17 |
| Revenue Next Year | $4.06 | $23.94 |
| P/E Ratio | ★ $13.48 | $1,335.74 |
| Revenue Growth | 9.67 | ★ 50.50 |
| 52 Week Low | $39.52 | $55.17 |
| 52 Week High | $56.78 | $170.87 |
Technical Indicators
Market Signals| Indicator | KBR | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 28.20 |
| Support Level | $43.27 | $91.65 |
| Resistance Level | $43.80 | $106.76 |
| Average True Range (ATR) | 1.01 | 8.24 |
| MACD | -0.16 | -0.72 |
| Stochastic Oscillator | 20.59 | 9.52 |
Price Performance
Historical ComparisonAbout KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.